Abiopharma

News list

Roivant Sciences Ltd. 🟢 acquired 16.7M shares of Immunovant, Inc. (IMVT) at $21.00 ($350.0M) Transaction Date: Dec 12, 2025 | Filing ID: 045409

Full text

News bot Dec. 12, 2025, 10:21 p.m.
🔍 Roivant Sciences Ltd. (Executive)

Company: Immunovant, Inc. (IMVT)

Report Date: 2025-12-12
Transaction Summary:
- Total transactions: 1
- Derivative instruments: 0
- Holdings reported: 0
- Total shares acquired: 16,666,666
Detailed Transactions and Holdings:
- Acquired 16,666,666 shares of Common Stock, $0.0001 par value per share at $21.0 per share (Direct)
  Date: 2025-12-12 | Code: P | equity_swap_involved: 0 | shares_owned_after: 113,317,007.00 | transaction_form_type: 4
Footnotes:
- REMARKS: The Reporting Person is deemed to be a "director by deputization" of the Issuer for purposes of Section 16 of the Securities Exchange Act of 1934 by virtue of the fact that Frank M. Torti, M.D. (who serves as President & Vant Chair of Roivant Sciences, Inc. ("RSI"), a subsidiary of the Reporting Person), Eric Venker, M.D., Pharm.D. (who serves as President of RSI) and Andrew Fromkin (who serves as the Vant Portfolio Operating Partner for RSI) each currently serve on the board of directors of the Issuer on behalf of the Reporting Person.